 |
|
| February 2004 |
|
| In This Issue
(click to link):
|
| Administrative
Reorganization |
The
HRA Board of Directors would like to inform you that
effective Tuesday, February 3, 2004, Matthew Purner has
been appointed Interim President & CEO of Health
Research Association.
We would like to reassure
our customers that there will be no interruption in
service during this transition. The Board and the
Management team look forward to working with you to
facilitate and expand the opportunities for clinical
research.
We welcome your input and cooperation
during this transition. If you have any questions,
please contact Matthew Purner at (323)
276-1403.
> > BACK TO
MENU
| HRA Training Seminar
Series |
Upcoming
Training Events
The next program offered by HRA
will be for Clinical Study Coordinators. The event will
take place on Thursday, April 1, at Hastings Auditorium.
The course is designed for Study Coordinators at
all levels and has been tailored to the needs of our
institution by the Training Committee, which includes
experienced USC Study Coordinators. Amgen will sponsor
the event and provide participants with course materials
as well as useful reference materials for ongoing use.
More details will be publicized as soon as they
are available. If you have questions about this or other
training events, please contact Debbie Waters at
323-223-4091.
> > BACK TO
MENU
| HRA New Projects Listing -
January
2004 |
Shelley
Shapiro
Medicine – Cardiovascular
"A
Phase III, Randomized, Double-Blind,
Placebo-Controlled Safety and Efficacy Study of
Sitaxsentan Sodium Treatment with an Open-Label
Bosentan Arm in Patients with Pulmonary Arterial
Hypertension"
Encysive Pharmaceuticals, Inc.
$46,130
Shelley Shapiro
Medicine –
Cardiovascular
"A Long-Term, Open-Label
Study to Evaluate the Safety of Sitaxsentan
Sodium Treatment in Patients with Pulmonary
Arterial Hypertension"
Encysive
Pharmaceuticals, Inc.
$72,315
Loren
Laine
Medicine – GI/Liver
"Double-Blind,
Placebo-Controlled, Randomized Two-Week Study,
Comparing Small Bowel Lesions Associated with
Celecoxib (200 mg BID) vs. Ibuprofen (800 mg
TID) plus Omeprazole (20 mg QD)"
Pfizer,
Inc.
$155,609
Juan
Asensio
Surgery
"The Utilization of
Adjunct Hemostatic Technologies: TissueLink
DS3.5 and its Application for Coagulation in an
Animal Model of Hepatic High Grade
Injuries"
TissueLink
Medical
$69,353.49
Robert
Beart
Surgery – Colon & Rectal
"A
Phase III, Multicenter, Double-Blind, Randomized
Study Evaluating Tigecycline and Linezolide for
the Treatment of Selected Serious Infections in
Subjects with Vancomycin-Resistant Enterococcus
and Evaluating Tigecycline and Vancomyclin for
the Treatment of Selected Serious Infections in
Subjects with Methicillin-Resistant
Staphylococcus"
Wyeth-Ayerst
Pharmaceuticals
$73,544.25
|
Donald
Minckler
Ophthalmology
Applanation
Tonometer
Eye-Deas,
LLC
$10,000
Andreas Kaiser
Surgery
– Colon & Rectal
"Acticon Neosphincter
Study: Effect of Standard Prophylactic
Antibiotic Regimen on Incidence of Postoperative
Infection"
American Medical
Systems
$8,750
Michael
Patzakis
Orthopedics
"A Phase III,
Multicenter, Double-Blind, Randomized Study
Evaluating Tigecycline and Linezolide for the
Treatment of Selected Serious Infections in
Subjects with Vancomycin-Resistant Enterococcus
and Evaluating Tigecycline and Vancomyclin for
the Treatment of Selected Serious Infections in
Subjects with Methicillin-Resistant
Staphylococcus"
Wyeth-Ayerst
Pharmaceuticals
$52,843.75
Lon
Schneider
Psychiatry
"Case Controlled
DNA/RNA/Serum/Plasma/Urine Banking in Subjects
with Dementia of the Alzheimer's
Disease"
PrecisionMed
$35,640
| |
> > BACK TO
MENU
Investigators:
Are you
seeking clinical trial study opportunities? Please take
a moment to review the latest clinical trial
opportunities from CenterWatch.
Medicure
Inc.
Ahmad Khalil
Email: akhalil@canambioresearch.com
Drug name: MC-1
Specialty: Cardiovascular
Surgery
Indication:
Eschemic-reperfusion injuries, MI and
stroke
Integrium
Marsha Klok
Email:
mklok@integrium.com
Drug name: Not available
Specialty:
Cardiology
Indication:
Angina
GlaxoSmithKline
Patricia
Haney
E-mail: patricia.haney-1@gsk.com
Drug
Name: Not available
Indication: Severe
sepsis
Specialty: Experienced
sites with the appropriate infrastructure to
identify this patient population and conduct ICU
based research trial. |
Cypress
Bioscience
Email: lmurphy@cypressbio.com
Drug
name: Milnacipran
Specialty: Rheumatology, Neurology, Pain
Management
Indication: Fibromyalgia
Syndrome (FMS)
Introgen Therapeutics,
Inc.
Lynn Pauwels
Email: l.pauwels@introgen.com
Drug
name: Advexin (INGN 201)
Specialty: Oncologist/ENT
Surgeon
Indication: Squamous Cell
Carcinoma of the Head and
Neck
NeurogesX
John Jermano, RN,
MPH
Email: jjermano@neurogesx.com
Drug
name: NGX-4010
Specialty: HIV Specialist;
Neurologist; Pain Management
Specialist
Indication: HIV
neuropathy
|
> > BACK TO
MENU
| HRA Employment
Opportunities |
HRA
has posted two new opportunities on the Employment
webpage (click to link):
* Receptionist - HRA Administrative
Office
* Nurse Practitioner/Physician's
Assistant- Hepatology Fellowship Program through
AASLD at Hepatitis Research And Treatment
Center
> > BACK TO
MENU
Important notice to all employees:
Upon changing your address and/or telephone number, you
must contact the HR department at HRA (323) 223-4091 to
avoid disruptions of the payroll process. Thank you for
your cooperation.
| HRA Payroll Dates |
| Time
Period |
Timesheet
Due |
Payday |
| 2/1 -
2/15 |
2/20 |
2/27 |
| 2/16 -
2/29 |
3/5 |
3/15 |
| 3/15 -
3/15 |
3/22 |
3/31 |
> > BACK TO
MENU
| Albert Yellin, MD,
Chairman |
Thomas Buchanan,
MD |
Daniel Mishell,
MD |
| Julian Haywood, MD,
Vice Chair |
Timothy Chan,
PhD |
John Nicoloff,
MD |
| Lawrence Opas, MD,
Treasurer |
Ronald Kaufman,
MD |
Darcy Spicer,
MD |
| Sol Bernstein, MD,
Medical Director |
Andrea Kovacs,
MD |
Cynthia Stotts, DO,
MS |
| David Altman, MD,
Secretary |
Karen Lindsay,
MD |
Joseph Van der
Meulen, MD |
| HRA Administrative Staff (with
links to
email) |
|
 | | |
